

PRIOR AUTHORIZATION POLICY

- POLICY:** Oncology (Injectable – Programmed Death-Ligand 1) – Bavencio Prior Authorization Policy
- Bavencio® (avelumab intravenous infusion – EMD Serono)

REVIEW DATE: 07/20/2022

OVERVIEW

Bavencio, a programmed cell death ligand-1 (PD-L1) blocking antibody, is indicated for the treatment of the following uses:¹

- **Merkel cell carcinoma**, in adults and pediatric patients ≥ 12 years of age with metastatic disease.
- **Renal cell carcinoma**, in combination with Inlyta (axitinib tablets), for the first-line treatment of patients with advanced disease.
- **Urothelial carcinoma**, in patients with locally advanced or metastatic disease who have **a**) disease progression during or following platinum-containing chemotherapy; or **b**) disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy; and for **c**) first-line maintenance treatment of locally advanced or metastatic disease that has not progressed with first-line platinum-containing chemotherapy.

Guidelines

Bavencio is addressed in National Comprehensive Cancer Network (NCCN) guidelines:

- **Bladder cancer** (version 2.2022 – May 20, 2022): Guidelines recommend Bavencio as an alternative preferred regimen for second-line therapy (category 2A) for locally advanced or metastatic disease (Stage IV).^{2,3} Guidelines also recommend Bavencio as maintenance therapy following platinum-based chemotherapy (category 1). The NCCN Compendium recommends Bavencio, as a single agent, for urothelial carcinoma of the bladder; for upper genitourinary tract tumors (metastatic disease); urothelial carcinoma of the prostate (metastatic disease); and for primary carcinoma of the urethra (recurrent or metastatic disease) as second-line or maintenance therapy.³
- **Gestational trophoblastic neoplasm** (version 1.2022 – October 6, 2021): Guidelines recommend Bavencio as a single agent for multidrug resistant high-risk disease, and recurrent or progressive intermediate trophoblastic tumor following a platinum-containing regimen.^{3,6}
- **Kidney cancer** (version 1.2023 – June 17, 2022): Guidelines recommend Bavencio in combination with Inlyta for first-line treatment for relapsed or Stage IV clear cell disease (category 2A).^{3,5} For subsequent therapy, Bavencio + Inlyta is a category 3 recommendation.
- **Merkel cell carcinoma** (version 2.2022 – March 24, 2022): Guidelines recommend Bavencio as one of the options for disseminated disease (category 2A).^{3,4} Clinical trial is preferred in this setting; but other PD-1/PD-L1 inhibitor options for disseminated disease include Keytruda® (pembrolizumab intravenous infusion) and Opdivo® (nivolumab intravenous infusion) [all category 2A].
- **Uterine Neoplasms** (version 1.2022 – November 4, 2021): Guidelines recommend Bavencio, as a single agent, for the treatment of recurrent or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors.^{3,7}

POLICY STATEMENT

07/20/2022

© 2022. All Rights Reserved.

This document is confidential and proprietary. Unauthorized use and distribution are prohibited.

Prior Authorization is recommended for prescription benefit coverage of Bavencio. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with Bavencio, as well as the monitoring required for adverse events and long-term efficacy, approval requires Bavencio to be prescribed by or in consultation with a physician who specializes in the condition being treated.

Automation: None.

RECOMMENDED AUTHORIZATION CRITERIA

Coverage of Bavencio is recommended in those who meet one of the following criteria:

FDA-Approved Indications

1. **Merkel Cell Carcinoma.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, and C):
 - A) Patient is ≥ 12 years of age; AND
 - B) Patient has metastatic (disseminated) Merkel cell carcinoma; AND
 - C) The medication is prescribed by or in consultation with an oncologist.
2. **Renal Cell Carcinoma.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, C, and D):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has relapsed or Stage IV clear cell disease; AND
 - C) The medication will be used in combination with Inlyta (axitinib tablets); AND
 - D) The medication is prescribed by or in consultation with an oncologist.
3. **Urothelial Carcinoma.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, C, and D):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has locally advanced or metastatic urothelial carcinoma; AND
 - C) Patient has tried platinum-containing chemotherapy (cisplatin or carboplatin); AND
 - D) The medication is prescribed by or in consultation with an oncologist.

Other Uses with Supportive Evidence

4. **Endometrial Carcinoma.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, C, D, and E):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has recurrent or metastatic disease; AND
 - C) Patient has microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors; AND
 - D) The medication will be used as a single agent; AND
 - E) The medication is prescribed by or in consultation with an oncologist.
5. **Gestational Trophoblastic Neoplasia.** Approve for 1 year if the patient meets ALL of the following criteria (A, B, C, and D):
 - A) Patient is ≥ 18 years of age; AND
 - B) Patient has multi-agent chemotherapy resistant disease; AND
 - C) The medication will be used as a single agent; AND

D) The medication is prescribed by or in consultation with an oncologist.

CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Bavencio is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES

1. Bavencio® intravenous infusion [prescribing information]. Rockland, MA: EMD Serono; November 2020.
2. The NCCN Bladder Cancer Clinical Practice Guidelines in Oncology (version 2.2022 – May 20, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 12, 2022.
3. The NCCN Drugs and Biologics Compendium. © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on July 12, 2022. Search term: avelumab.
4. The NCCN Merkel Cell Carcinoma Clinical Practice Guidelines in Oncology (version 2.2022 – March 24, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 12, 2022.
5. The NCCN Kidney Cancer Clinical Practice Guidelines in Oncology (version 1.2023 – June 17, 2022). © 2022 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 12, 2022.
6. The NCCN Gestational Trophoblastic Neoplasia Clinical Practice Guidelines in Oncology (version 1.2022 – October 6, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 12, 2022.
7. The NCCN Uterine Neoplasms Clinical Practice Guidelines in Oncology (version 1.2022 – November 4, 2021). © 2021 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed July 12, 2022.